1460778148-dc0bd3be-da01-4bcb-a678-37d8a849e025

1. A device for deploying an intraocular shunt, the device comprising:
a housing;
a hollow shaft, coupled to the housing, configured to hold an intraocular shunt;
a plunger, slidably disposed within the shaft;
a rotating component, coupled to the housing, having first and second slots;
a pusher component, coupled to the plunger, having a first member that resides within the first slot to couple the pusher component with the rotating component such that rotation of the rotating component causes distal axial movement of the first member, thereby urging the plunger in a distal axial direction to advance the shunt partially from within the shaft; and
a retraction component, coupled to the shaft, having a second member that resides within the second slot to couple the retraction component with the rotating component such that further rotation of the rotating component causes proximal axial movement of the second member, thereby urging the shaft in a proximal axial direction relative to the shunt.
2. The device according to claim 1, wherein at least a portion of the first slot and at least a portion of the second slot extend diagonally relative to a longitudinal axis of the rotating component.
3. The device according to claim 1, wherein the shaft is configured to at least partially retract to within the housing.
4. The device according to claim 3, wherein the shaft fully retracts to within the housing.
5. The device according to claim 1, further comprising an intraocular shunt that is at least partially disposed within the shaft.
6. The device according to claim 1, wherein the deployment mechanism further comprises at least one member that limits axial movement of the shaft.
7. The device according to claim 1, wherein the hollow shaft comprises a needle.
8. The device according to claim 1, wherein a distal portion of the housing comprises a sleeve and the hollow shaft is movable within the sleeve.
9. A device for deploying an intraocular shunt, the device comprising:
a housing;
a hollow shaft, coupled to the housing, configured to hold an intraocular shunt;
a plunger slidably disposed within the shaft;
a deployment mechanism at least partially disposed within the housing, the deployment mechanism comprising a rotating component, a pusher component coupled to the plunger, and a retraction component coupled to the shaft, the rotating component being operably coupled to the pusher and retraction components by first and second slots and first and second protruding members slidably disposed within the respective first and second slots;
wherein rotation of the rotating component causes (i) axial movement of the pusher component to urge the plunger distally relative to the shaft and the housing and (ii) axial movement of the retraction component to urge the shaft proximally relative to the plunger and the housing.
10. The device according to claim 9, wherein the rotating component is configured to sequentially engage the pusher component and then the retraction component.
11. The device according to claim 9, wherein rotating component comprises the first and second slots.
12. The device according to claim 11, wherein the pusher component comprises the first protrusion and the retraction component comprises the second protrusion.
13. The device according to claim 9, wherein the shaft fully retracts to within the housing.
14. The device according to claim 9, further comprising an intraocular shunt that is at least partially disposed within the shaft.
15. The device according to claim 9, wherein the deployment mechanism further comprises at least one member that limits axial movement of the shaft.
16. The device according to claim 9, wherein a distal portion of the housing comprises a sleeve and the hollow shaft is movable within the sleeve.
17. A device for deploying an intraocular shunt, the device comprising:
a housing;
a deployment mechanism at least partially disposed within the housing, the deployment mechanism comprising a rotating component, a pusher component, and a retraction component, the rotating component being operably coupled to the pusher and retraction components by first and second slots and first and second protruding members slidably disposed within the respective first and second slots;
wherein rotation of the rotating component causes (i) distal axial movement of the pusher component relative to the housing to push a stent within the device, and (ii) proximal axial movement of the retraction component to expose the stent from the device.
18. The device according to claim 17, further comprising a hollow shaft coupled to the housing and a plunger slidably disposed within the shaft, wherein the shaft is coupled to the retraction component and the plunger is coupled to the pusher component.
19. The device according to claim 17, wherein the housing comprises a sleeve and the pusher and retraction components are movable relative to the sleeve.
20. The device according to claim 17, wherein the rotating component comprises the first and second slots, the pusher component comprises the first protruding member, and the retraction component comprises the second protruding member.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A compound of the formula I,
wherein
A is selected from R11\u2014O\u2014C(O)\u2014, R12\u2014N(R13)\u2014C(O)\u2014 and Het1;
R1, R2, R3 and R4 are independently selected from hydrogen, halogen, (C1-C4)-alkyl, Ar\u2014(C1-C4)-alkyl-, Ar, Het2, (C1-C4)-alkyl-C(O)\u2014, Ar\u2014C(O)\u2014, cyano, R14\u2014N(R15)\u2014C(O)\u2014, Het3-C(O)\u2014, hydroxy, (C1-C4)-alkyl-O\u2014, Ar\u2014O\u2014, Ar\u2014(C1-C4)-alkyl-O\u2014, (C1-C4)-alkyl-S(O)n\u2014, Ar\u2014S(O)n\u2014, R11\u2014N(R12)\u2014S(O)2\u2014, Het3-S(O)2\u2014, (C1-C4)-alkyl-NH\u2014, di((C1-C4)-alkyl)N\u2014, Ar\u2014NH\u2014 and Ar\u2014N((C1-C4)-alkyl)-,
and either R1 and R2, or R2 and R3, or R3 and R4, together with the carbon atoms carrying them, can form a carbocyclic ring selected from benzene and 5-membered to 7-membered cycloalkane, wherein the benzene ring is unsubstituted or substituted by one or more substituents independently selected from halogen, (C1-C4)-alkyl, cyano, (C1-C4)-alkyl-O\u2014 and (C1-C4)-alkyl-S(O)n\u2014, and the cycloalkane ring is unsubstituted or substituted by one or more substituents independently selected from fluorine and (C1-C4)-alkyl;
R5 is selected from hydrogen and (C1-C4)-alkyl;
R11, R12, R13, R14 and R15 are independently selected from hydrogen and (C1-C4)-alkyl;
one of the groups Z1 and Z2 is (C3-C8)-cycloalkyl and the other is selected from hydrogen, (C1-C8)-alkyl, (C3-C8)-cycloalkyl and phenyl, wherein all cycloalkyl groups are independently unsubstituted or substituted by one or more substituents independently selected from fluorine, (C1-C4)-alkyl and (C1-C4)-alkyl-O\u2014, and the phenyl group is unsubstituted or substituted by one or more substituents independently selected from halogen, (C1-C4)-alkyl, cyano, (C1-C4)-alkyl-O\u2014 and (C1-C4)-alkyl-S(O)n\u2014;
Ar is phenyl or an aromatic, 5-membered or 6-membered, monocyclic heterocycle which comprises one or two ring heteroatoms independently selected from N, O and S, which are all unsubstituted or substituted by one or more substituents independently selected from halogen, (C1-C4)-alkyl, cyano, (C1-C4)-alkyl-O\u2014 and (C1-C4)-alkyl-S(O)n\u2014;
Het1 is a partially unsaturated or aromatic, 5-membered or 6-membered, monocyclic heterocycle which comprises one to four ring heteroatoms independently selected from N, O and S, bonded via a ring carbon atom, and unsubstituted or substituted by one or more substituents independently selected from (C1-C4)-alkyl, hydroxy and oxo;
Het2 is a saturated, 4-membered to 7-membered, monocyclic heterocycle which comprises one or two ring heteroatoms independently selected from N, O and S, bonded via a ring carbon atom or a ring nitrogen atom, and unsubstituted or substituted by one or more substituents independently selected from fluorine and (C1-C4)-alkyl;
Het3 is a saturated 4-membered to 7-membered, monocyclic heterocycle which comprises a ring nitrogen atom via which Het3 is bonded, and zero or one further ring heteroatom selected from N, O and S, and unsubstituted or substituted by one or more substituents independently selected from fluorine and (C1-C4)-alkyl;
n is selected from the numbers 0, 1 and 2;

wherein
all alkyl groups are unsubstituted or substituted by one or more fluorine substituents;

in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a pharmaceutically acceptable salt thereof;
provided that the compound of the formula I is not
6-chloro-4-cyclohexyl-4-phenyl-4H-benzo1,3dioxine-2-carboxylic acid,
6-chloro-4-cyclohexyl-4-phenyl-4H-benzo1,3dioxine-2-carboxylic acid methyl ester, or
6-chloro-4,4-dicyclohexyl-4H-benzo1,3dioxine-2-carboxylic acid.
2. A compound of the formula I according to claim 1, wherein
A is selected from R11\u2014O\u2014C(O)\u2014, R12\u2014N(R13)\u2014C(O)\u2014 and Het1;
R1, R2, R3 and R4 are independently selected from hydrogen, halogen, (C1-C4)-alkyl, Ar\u2014(C1-C4)-alkyl-, Ar, Het2, (C1-C4)-alkyl-C(O)\u2014, Ar\u2014C(O)\u2014, R14\u2014N(R15)\u2014C(O)\u2014, Het3-C(O)\u2014, (C1-C4)-alkyl-O\u2014, Ar\u2014O\u2014, Ar\u2014(C1-C4)-alkyl-O\u2014, (C1-C4)-alkyl-S(O)n\u2014, Ar\u2014S(O)n\u2014, R11\u2014N(R12)\u2014S(O)2\u2014, Het3-S(O)2\u2014, (C1-C4)-alkyl-NH\u2014 and di((C1-C4)-alkyl)N\u2014,
and either R1 and R2, or R2 and R3, or R3 and R4, together with the carbon atoms carrying them, can form a carbocyclic ring selected from benzene and 5-membered or 6-membered cycloalkane, wherein the benzene ring is unsubstituted or substituted by one or more substituents independently selected from halogen and (C1-C4)-alkyl, and the cycloalkane ring is unsubstituted or substituted by one or more substituents independently selected from fluorine and (C1-C4)-alkyl;
R5 is selected from hydrogen and (C1-C4)-alkyl;
R11, R12, R13, R14 and R15 are independently selected from hydrogen and (C1-C4)-alkyl;
one of the groups Z1 and Z2 is (C3-C8)-cycloalkyl and the other is selected from hydrogen, (C1-C8)-alkyl, (C3-C8)-cycloalkyl and phenyl, wherein all cycloalkyl groups are independently unsubstituted or substituted by one or more substituents independently selected from fluorine, (C1-C4)-alkyl and (C1-C4)-alkyl-O\u2014, and the phenyl group is unsubstituted or substituted by one or more substituents independently selected from halogen, (C1-C4)-alkyl, cyano, (C1-C4)-alkyl-O\u2014 and (C1-C4)-alkyl-S(O)n\u2014;
Ar is phenyl or an aromatic, 5-membered or 6-membered, monocyclic heterocycle which comprises one or two ring heteroatoms independently selected from N, O and S, which are all unsubstituted or substituted by one or more substituents independently selected from halogen, (C1-C4)-alkyl, cyano, (C1-C4)-alkyl-O\u2014 and (C1-C4)-alkyl-S(O)n\u2014;
Het1 is a partially unsaturated or aromatic, 5-membered monocyclic heterocycle which comprises one to four ring heteroatoms independently selected from N, O and S, bonded via a ring carbon atom, and unsubstituted or substituted by one or more substituents independently selected from (C1-C4)-alkyl, hydroxy and oxo;
Het2 is a saturated, 4-membered to 7-membered, monocyclic heterocycle which comprises one or two ring heteroatoms independently selected from N, O and S, bonded via a ring carbon atom or a ring nitrogen atom, and unsubstituted or substituted by one or more substituents independently selected from fluorine and (C1-C4)-alkyl;
Het3 is a saturated 4-membered to 7-membered, monocyclic heterocycle which comprises a ring nitrogen atom via which Het3 is bonded, and zero or one further ring heteroatom selected from N, O and S, and unsubstituted or substituted by one or more substituents independently selected from fluorine and (C1-C4)-alkyl;
n is selected from the numbers 0, 1 and 2;

wherein
all alkyl groups are unsubstituted or substituted by one or more fluorine substituents;

in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a pharmaceutically acceptable salt thereof.
3. A compound of the formula I according to claim 1, wherein
A is selected from R11\u2014O\u2014C(O)\u2014 or Het1;
R1, R2, R3 and R4 are independently selected from hydrogen, halogen, (C1-C4)-alkyl, Ar\u2014(C1-C4)-alkyl-, Ar, Het2, (C1-C4)-alkyl-C(O)\u2014, Ar\u2014C(O)\u2014, R14\u2014N(R15)\u2014C(O)\u2014, Het3-C(O)\u2014, (C1-C4)-alkyl-O\u2014, Ar\u2014O\u2014, Ar\u2014(C1-C4)-alkyl-O\u2014, (R11\u2014N(R12)\u2014S(O)2\u2014, Het3-S(O)2\u2014, (C1-C4)-alkyl-NH\u2014 and di((C1-C4)-alkyl)N\u2014,
and either R1 and R2, or R2 and R3, or R3 and R4, together with the carbon atoms carrying them, can form a carbocyclic ring selected from benzene and 5-membered or 6-membered cycloalkane, wherein the benzene ring is unsubstituted or substituted by one or more substituents independently selected from halogen and (C1-C4)-alkyl, and the cycloalkane ring is unsubstituted or substituted by one or more substituents independently selected from fluorine and (C1-C4)-alkyl;
R5 is selected from hydrogen and (C1-C4)-alkyl;
R11, R12, R14 and R15 are independently selected from hydrogen and (C1-C4)-alkyl;
one of the groups Z1 and Z2 is (C3-C8)-cycloalkyl and the other is selected from hydrogen, (C1-C4)-alkyl, (C3-C8)-cycloalkyl and phenyl, wherein all cycloalkyl groups are independently unsubstituted or substituted by one or more substituents independently selected from fluorine and (C1-C4)-alkyl, and the phenyl group is unsubstituted or substituted by one or more substituents independently selected from halogen and (C1-C4)-alkyl;
Ar is phenyl or an aromatic, 5-membered or 6-membered, monocyclic heterocycle which comprises one or two ring heteroatoms independently selected from N, O and S, which are all unsubstituted or substituted by one or more substituents independently selected from halogen, (C1-C4)-alkyl and (C1-C4)-alkyl-O\u2014;
Het1 is selected from
wherein R10 is selected from hydrogen and (C1-C4)-alkyl;
Het2 is a saturated, 5-membered or 6-membered, monocyclic heterocycle which comprises one or two ring heteroatoms independently selected from N, O and S, bonded via a ring carbon atom or a ring nitrogen atom, and unsubstituted or substituted by one or more substituents independently selected from fluorine and (C1-C4)-alkyl;
Het3 is a saturated 5-membered or 6-membered, monocyclic heterocycle which comprises a ring nitrogen atom via which Het3 is bonded, and zero or one further ring heteroatom selected from N, O and S, and unsubstituted or substituted by one or more substituents independently selected from fluorine and (C1-C4)-alkyl;

wherein
all alkyl groups are unsubstituted or substituted by one or more fluorine substituents;

in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a pharmaceutically acceptable salt thereof.
4. A compound of the formula I according to claim 1, wherein
A is selected from R11\u2014O\u2014C(O)\u2014,
R1, R2, R3 and R4 are independently selected from hydrogen, halogen, (C1-C4)-alkyl, (C1-C4)-perfluoroalkyl, (C1-C4)-alkyl-O\u2014, (C1-C4)-perfluoroalkyl-O\u2014, phenyl, pyrrolyl, pyridinyl, pyridinyl-O\u2014, pyrrolidinyl-S(O)2\u2014, morpholinyl, Ar\u2014C(O)\u2014, Ar\u2014O\u2014, di((C1-C4)-alkyl)N\u2014, Ar\u2014(C1-C4)-alkyl- and Ar\u2014(C1-C4)-alkyl-O\u2014,
and either the groups R1 and R2, or R2 and R3, or R3 and R4, together with the carbon atoms carrying them, can form a benzene ring or a cyclohexane ring, wherein the benzene ring is unsubstituted or substituted by one or more substituents independently selected from halogen and (C1-C4)-alkyl, and the cyclohexane ring is unsubstituted or substituted by one or more substituents independently selected from fluorine and (C1-C4)-alkyl;
R5 is hydrogen or methyl;
Z1 and Z2 are identical and are (C3-C8)-cycloalkyl,
or one of the residues Z1 and Z2 is (C3-C8)-cycloalkyl and the other is hydrogen or phenyl;
Ar is phenyl unsubstituted or substituted by one or two substituents independently selected from halogen and (C1-C4)-alkyl-O\u2014;

in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a pharmaceutically acceptable salt thereof.
5. A compound of the formula I according to claim 1, selected from
4,4-Dicyclohexyl-7-pyrrol-1-yl-4H-benzo1,3dioxine-2-carboxylic acid,
4,4-Dicyclohexyl-6-methyl-4H-benzo1,3dioxine-2-carboxylic acid,
4,4-Dicyclohexyl-7-methoxy-4H-benzo1,3dioxine-2-carboxylic acid,
4,4-Dicyclohexyl-6-fluoro-4H-benzo1,3dioxine-2-carboxylic acid,
4,4-Dicyclohexyl-7-dimethylamino-4H-benzo1,3dioxine-2-carboxylic acid,
4,4-Dicyclohexyl-5,7-dimethoxy-4H-benzo1,3dioxine-2-carboxylic acid,
4,4-Dicyclohexyl-4H-naphtho2,3-d1,3dioxine-2-carboxylic acid,
4,4-Dicyclohexyl-7-methyl-4H-benzo1,3dioxine-2-carboxylic acid,
4,4-Dicyclohexyl-5-methyl-4H-benzo1,3dioxine-2-carboxylic acid,
7-Chloro-4,4-dicyclohexyl-4H-benzo1,3dioxine-2-carboxylic acid,
4,4-Dicyclohexyl-8-methyl-4H-benzo1,3dioxine-2-carboxylic acid,
4,4-Dicyclohexyl-8-fluoro-4H-benzo1,3dioxine-2-carboxylic acid,
6-tert-Butyl-4,4-dicyclohexyl-4H-benzo1,3dioxine-2-carboxylic acid,
4,4-Dicyclohexyl-6-iodo-4H-benzo1,3dioxine-2-carboxylic acid,
4,4-Dicyclohexyl-6-trifluoromethyl-4H-benzo1,3dioxine-2-carboxylic acid,
6-Chloro-4,4-dicyclohexyl-2-methyl-4H-benzo1,3dioxine-2-carboxylic acid,
4,4-Dicyclohexyl-6-trifluoromethoxy-4H-benzo1,3dioxine-2-carboxylic acid,
6-Chloro-4,4-dicyclohexyl-7-fluoro-4H-benzo1,3dioxine-2-carboxylic acid,
6-Chloro-4,4-dicyclohexyl-8-fluoro-4H-benzo1,3dioxine-2-carboxylic acid,
6-Chloro-4,4-dicyclohexyl-5-fluoro-4H-benzo1,3dioxine-2-carboxylic acid,
6-(4-Chloro-phenoxy)-4,4-dicyclohexyl-4H-benzo1,3dioxine-2-carboxylic acid,
4,4-Dicyclohexyl-6-pyridin-4-yl-4H-benzo1,3dioxine-2-carboxylic acid,
4,4-Dicyclohexyl-6-(3-methoxy-phenoxy)-4H-benzo1,3dioxine-2-carboxylic acid,
6-(3-Chloro-phenoxy)-4,4-dicyclohexyl-4H-benzo1,3dioxine-2-carboxylic acid,
6-(4-Chloro-benzoyl)-4,4-dicyclohexyl-4H-benzo1,3dioxine-2-carboxylic acid,
4,4-Dicyclohexyl-6-(pyridin-3-yloxy)-4H-benzo1,3dioxine-2-carboxylic acid,
4,4-Dicyclohexyl-4H-benzo1,3dioxine-2-carboxylic acid,
4,4-Dicyclohexyl-8-methoxy-4H-benzo1,3dioxine-2-carboxylic acid,
4,4-Dicyclohexyl-5-ethoxy-4H-benzo1,3dioxine-2-carboxylic acid,
7-Butoxy-4,4-dicyclohexyl-4H-benzo1,3dioxine-2-carboxylic acid,
6,8-Dichloro-4,4-dicyclohexyl-4H-benzo1,3dioxine-2-carboxylic acid,
1,1-Dicyclohexyl-1H-naphtho2,1-d1,3dioxine-3-carboxylic acid,
4,4-Dicyclohexyl-6-methoxy-4H-benzo1,3dioxine-2-carboxylic acid,
4,4-Dicyclohexyl-6-phenyl-4H-benzo1,3dioxine-2-carboxylic acid,
4,4-Dicyclohexyl-7-methoxy-5-methyl-4H-benzo1,3dioxine-2-carboxylic acid,
7-Benzyloxy-4,4-dicyclohexyl-4H-benzo1,3dioxine-2-carboxylic acid,
6-Chloro-4,4-dicyclohexyl-7-methoxy-4H-benzo1,3dioxine-2-carboxylic acid,
4,4-Dicyclohexyl-6-(pyrrolidine-1-sulfonyl)-4H-benzo1,3dioxine-2-carboxylic acid,
4,4-Dicyclohexyl-7-morpholin-4-yl-4H-benzo1,3dioxine-2-carboxylic acid,
4,4-Dicyclohexyl-4H-naphtho1,2-d1,3dioxine-2-carboxylic acid,
6-Chloro-4,4-dicyclohexyl-8-methyl-4H-benzo1,3dioxine-2-carboxylic acid,
6-Chloro-4,4-dicyclohexyl-7-methyl-4H-benzo1,3dioxine-2-carboxylic acid,
4,4-Dicyclohexyl-5,7-difluoro-4H-benzo1,3dioxine-2-carboxylic acid,
1,1-Dicyclohexyl-7,8,9,10-tetrahydro-1H-naphtho2,1-d1,3dioxine-3-carboxylic acid,
4,4-Dicyclohexyl-8-trifluoromethoxy-4H-benzo1,3dioxine-2-carboxylic acid,
8-tert-Butyl-4,4-dicyclohexyl-4H-benzo1,3dioxine-2-carboxylic acid,
10-Benzyl-4,4-dicyclohexyl-4H-naphtho2,3-d1,3dioxine-2-carboxylic acid,
4,4-Dicyclohexyl-7-diethylamino-4H-benzo1,3dioxine-2-carboxylic acid,
6-Bromo-4,4-dicyclohexyl-4H-benzo1,3dioxine-2-carboxylic acid,
6-Chloro-4,4-dicyclopentyl-4H-benzo1,3dioxine-2-carboxylic acid,
6-Chloro-4-cycloheptyl-4H-benzo1,3dioxine-2-carboxylic acid,
6-Bromo-4,4-dicyclohexyl-4H-benzo1,3dioxine-2-carboxylic acid,
6-Chloro-4,4-dicycloheptyl-4H-benzo1,3dioxine-2-carboxylic acid,
6-Chloro-4,4-dicyclooctyl-4H-benzo1,3dioxine-2-carboxylic acid,
6-Chloro-4,4-dicycloheptyl-7-methyl-4H-benzo1,3dioxine-2-carboxylic acid,
4,4-Dicycloheptyl-6-trifluoromethoxy-4H-benzo1,3dioxine-2-carboxylic acid,
6-Bromo-4,4-dicycloheptyl-4H-benzo1,3dioxine-2-carboxylic acid,
5-(6-Chloro-4,4-dicyclohexyl-4H-benzo1,3dioxin-2-yl)-1H-tetrazole,
3-(6-Chloro-4,4-dicyclohexyl-4H-benzo1,3dioxin-2-yl)-4H-1,2,4oxadiazol-5-one,
6-Chloro-4,4-dicyclohexyl-4H-benzo1,3dioxine-2-carboxylic acid methyl ester, and
5-(6-Chloro-4,4-dicyclohexyl-4H-benzo1,3dioxin-2-yl)-3H-1,3,4oxadiazol-2-one,
in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a pharmaceutically acceptable salt thereof.
6. A pharmaceutical composition comprising a compound of the formula I according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
7. A method for the treatment of a disease responsive to the inhibition of the LPA receptor LPAR5, or for the reduction or inhibition of platelet aggregation, thrombus formation, activation of mast cells, or activation of microglial cells in a patient in need thereof, the method comprising administering a compound of the formula I according to claim 1, or a pharmaceutically acceptable salt thereof.
8. A method for the treatment of thromboembolic diseases, deep vein thrombosis, venous or arterial thromboembolism, thrombophlebitis, coronary or cerebral arterial thrombosis, cerebral embolism, renal embolism, pulmonary embolism, disseminated intravascular coagulation, cardiovascular disorders, transient ischemic attacks, strokes, acute myocardial infarction, peripheral vascular disease, preeclampsiaeclampsia, thrombotic cytopenic purpura, inflammatory disorders, hyperalgesia, asthma, multiple sclerosis, inflammatory pain, angiogenesis, allergic responses, or restenosis in a patient in need thereof, the method comprising administering a compound of the formula I according to claim 1, or a pharmaceutically acceptable salt thereof.
9. A method for the treatment of abnormal thrombus formation, acute myocardial infarction, thromboembolism, acute vessel closure associated with thrombolytic therapy or percutaneous transluminal coronary angioplasty (PTCA), transient ischemic attacks, stroke, intermittent claudication, bypass grafting of the coronary or peripheral arteries, vessel luminal narrowing, restenosis post coronary or venous angioplasty, maintenance of vascular access patency in long-term hemodialysis patients, pathologic thrombus formation occurring in the veins of the lower extremities following abdominal, knee or hip surgery, a risk of pulmonary thromboembolism, or disseminated systemic intravascular coagulatopathy occurring in vascular systems during septic shock, viral infections or cancer in a patient in need thereof, the method comprising administering a compound of the formula I according to claim 1, or a pharmaceutically acceptable salt thereof.
10. A method for the treatment of inflammatory pain, asthma, angiogenesis, demyelating diseases of the central nervous system or the peripheral nervous system, multiple sclerosis, transverse myelitis, optic neuritis, Devic’s disease, Guillain-Barre syndrome or chronic inflammatory demyelinating polyneuropathy in a patient in need thereof, the method comprising administering a compound of the formula I according to claim 1, or a pharmaceutically acceptable salt thereof.